Travere Therapeutics(TVTX)
Focus: Travere Therapeutics is a public biotech focused on rare kidney diseases and metabolic disorders, with a mid-cap footprint of 201-500 employees generating $145M in FY2025 revenue.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
54-6 this month
Cooling — net -6 jobs in 30d
24 added, 30 removed. Slower than typical.
Should You Work at Travere Therapeutics?
AI assessmentTravere offers exposure to high-growth rare disease markets with a marketed product, but extreme revenue concentration and negative cash position make it a higher-risk career move suitable only for candidates comfortable with restructuring or M&A scenarios.
Why Work Here
- Focused nephrology and rare disease portfolio with meaningful commercial traction: FILSPARI generated $145M revenue in FY2025, up 33% YoY.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
1 in 5yr
FILSPARI
Hiring
Stable
Revenue
$145M
Help build intelligence for Travere Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.